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doi:10.1016/j.asjsur.2011.08.005Summary Objective: Liver transplantation (LT) is known to be a promising treatment for
patients with liver cirrhosis associated with hepatocellular carcinoma (HCC). This study,
however, found that HCC recurrence remains to be a concern.
Methods: A total of 126 HCC patients who had undergone LT between January 2000 and
December 2009 were retrospectively reviewed. The clinicopathological features of the
patients were analyzed by univariate and multivariate analyses to determine prognostic
factors. Patients who had HCC recurrence were further analyzed in terms of recurrent pattern,
management, and outcome.
Results: Seventeen patients (13.5%) exhibited HCC recurrence following LT. Univariate and
multivariate analyses identified two prognostic factors: tumor number > three [hazard ratio
(HR)Z 3.249] and presence of microvascular invasion (HRZ 4.336). Among patients with HCC
recurrence, 15 out of 17 (88%) patients developed extrahepaticmetastasis shortly after recurrence.
The survival of patients after HCC recurrence was dismal with 18.3 months of median survival.
Conclusions: Multiple tumors (>three) are an important prognostic factor for HCC recurrence
following LT, but an accurate assessment of tumor status by pretransplantation radiological exam-
ination is required.TheoutcomeofpatientswithHCCrecurrenceafter LTremains verypoorbecause
of a tendency of HCC to recur as extrahepatic metastasis.
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HCC recurrence after transplantation 1291. Introduction Primary HCC treatment consisted of a multimodalHepatocellular carcinoma (HCC) is a common but lethal
malignant disease with worldwide occurrence, and
majority of the cases are associated with liver cirrhosis.
Although hepatic resection is the preferred treatment that
provides a favorable outcome for HCC patients, the
proportion of suitable patients is limited by the underlying
liver cirrhosis and poor liver function reserve. Therefore,
liver transplantation (LT) was introduced as a promising
treatment modality that simultaneously cures liver cirrhosis
and HCC. Nonetheless, the initial results of LT were frus-
trating until the Milan criteria were proposed in 1996.1e3
The results of LT in HCC patients meeting the Milan
criteria are excellent in terms of HCC recurrence and
patients’ outcome; this fact has facilitated the worldwide
use of these criteria for patient selection. Subsequently,
expanded criteria, including the University of California,
San Francisco (UCSF), and the up-to-seven criteria, were
introduced to recruit more patients qualifying for LT, and
this generated valuable results.4e6
However, HCC patients meeting these criteria are not
completely free from the risk of tumor recurrence after LT.
It is estimated that around 10e20% of the patients expe-
rienced HCC recurrence despite meeting these criteria.7e10
Therefore, prediction of HCC recurrence following LT
remains entirely elusive, and despite a growing experience
and literature, it is still a hotly debated field. Therefore, in
this study, we aimed to identify the factors associated with
the prognosis of HCC patients undergoing LT, and to
analyze the outcome of patients with HCC recurrence
following LT.
2. Materials and methods
2.1. Patients
A total of 376 LTs were performed at the Organ Trans-
plantation Institute of Chang Gung Memorial Hospital at
Linkou, Taiwan, between January 2000 and December 2009.
A retrospective review of the database showed that 137
patients had undergone LT because of HCC-associated liver
cirrhosis. Apart from 11 (8.0%) hospital mortalities, the
remaining 126 patients, including 97 men and 29 women
with their ages ranging from 32 to 68 years
[mean  standard deviation (SD), 53.0  7.3 years], were
enrolled in the current study.
2.2. Diagnosis and treatment of HCC
The diagnosis of HCC was based on the findings of ultraso-
nography, computed tomography (CT), hepatic angiog-
raphy, and/or magnetic resonance imaging (MRI), in
accordance with the European Association for the Study of
the Liver (EASL) guidelines and the American Association
for the Study of Liver Diseases (AASLD) guidelines.11,12
Ultrasound-guided biopsy was considered only in the case
of equivocal imaging patterns and/or when clinically indi-
cated; the concentration of the serological tumor marker,
a-fetoprotein (AFP), was also assessed during diagnosis.therapy, including hepatic resection, local ablation by
radiofrequency ablation or percutaneous ethanol injection,
transcatheter arterial chemoembolization (TACE), and an
eventual referral for LT, or a combination of these treat-
ments; the treatment was decided based on the consensus
of the liver cancer committee composed of representatives
from the liver surgery, oncology, hepatology, radiology, and
interventional radiology departments. Treatment options
mainly depend on tumor characteristics and the patient’s
physical condition, and hepatic resection is always consid-
ered a preferred treatment. In particular, a patient with
unresectable HCC and willing to undergo transplantation
was evaluated for LT, but patients with imaging evidences
of extrahepatic metastasis or vascular invasion were
considered unsuitable for LT. HCC patients were listed in
the waitlist only if they met the proposed Milan criteria1:
single tumor 5 cm or up to three tumors, none >3 cm
before 2002. They also needed to meet the expanded
criteria from UCSF5: single tumor 6.5 cm, or three
tumors, none >3 cm with a total tumor diameter of 8 cm
after 2002. TACE and local ablation were arranged to
prevent tumor progression for patients who were potential
transplantation candidates with HCC beyond the trans-
plantation criteria; downstage patients awaiting
a deceased donor LT; patients with different reasons for
being unable to undergo LT within 3 months and for whom
we anticipated a longer waiting time; etc.
The strategy for the treatment of recurrent HCC after LT
was the same as that for primary HCC, depending on the
consensus of the liver cancer committee.
2.3. Variables and clinicopathological features
Variables including demographics, laboratory data, trans-
plantation features, and tumor characteristics were
analyzed to determine the prognostic factors. Tumor
characteristics were determined by the histopathological
examination of the thin-sliced specimens (at 5 mm inter-
vals) of the explanted liver.
2.4. Transplantation and follow-up
All LTs were performed using standard techniques without
venovenous bypass. Postoperative immunosuppression
consisted of two protocols: methylprednisolone plus
cyclosporine for recipients who underwent transplantation
before the introduction of tacrolimus, and a combination of
three drugs including methylprednisolone, tacrolimus, and
mycophenolate mofetil for patients who underwent trans-
plantation after the introduction of tacrolimus. However,
all immunosuppression procedures were switched to the
latter protocol since 2001. Of these three drugs, the dose of
methylprednisolone was tapered and discontinued by the
third postoperative month in the majority of the recipients,
while tacrolimus and mycophenolate mofetil were
continued for the maintenance of immunosuppression.
Serum levels of tacrolimus were kept at 5 ng/mL to 10 ng/
mL as much as possible. Patients were aggressively fol-
lowed up for tumor recurrence by AFP measurements and
liver ultrasonography at monthly intervals in the initial
Table 1 Clinicopathological characteristics of patients
with and without HCC recurrence.
Characteristics HCC recurrence p value
Yes (n Z 17) No (n Z 109)
Age (years), mean
(range)
48.9 (32e63) 53.7 (33e68) 0.029
Sex (Male:Female) 15:2 82:27 0.381
Hepatitis status
Hepatitis B
positive
13 (76.5%) 73 (67.0%) 0.297
Hepatitis C
positive
2 (11.7%) 29 (26.6%)
Hepatitis B
and C positive
1 (5.9%) 5 (4.6%)
None 1 (5.9%) 2 (1.8% )
Child-Pugh Class
A 7 (41.2%) 33 (30.3%) 0.566
B 5 (29.4%) 43 (39.4%)
C 5 (29.4%) 33 (30.3%)
MELD score,
median (range)
16 (8e41) 15 (7e40) 0.378
AFP (ng/ml),
median (range)
54 (3e18250) 14 (2e1360) 0.081
Liver transplantation type
DDLT 3 (17.6%) 33 (30.3%) 0.433
LDLT 14 (82.4%) 76 (69.7%)
Meeting Milan
criteria
6 (35.3%) 87 (79.8%) <0.001
Meeting UCSF
criteria
9 (52.9%) 96 (88.1%) 0.001
HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; MELD:
model for end-stage liver disease; DDLT: deceased donor liver
transplantation; LDLT: living donor liver transplantation; UCSF:
University of California, San Francisco.
130 K.-M. Chan et al.3 months and every 3 months thereafter. CT and/or MRI
were performed annually or whenever HCC recurrence was
suspected.
2.5. Statistical analysis
All the data were analyzed using the statistical software
SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) and Prism
version 5.0 (GraphPad Software, San Diego, CA, USA) for
Windows. The outcome measurements included
Recurrence-Free Survival (RFS) and overall survival. RFS
was calculated from the date of LT to the date of HCC
recurrence. Overall survival was measured from the date of
LT to the date of death. Analyses of the variables were
performed using the Cox proportional hazards regression
model in order to identify the factors that influence RFS,
and all the prognostic factors with a p value of <0.1 from
univariate analysis were then selected for multivariate
analysis in a forward stepwise manner. Cut-off values for
the tumor factor in the statistical analysis were defined
according to previous reports or transplantation criteria of
Milan and UCSF. Differences in clinicopathological features
among the groups were assessed using Chi-square or
Fisher’s exact test. Survival rates were calculated by the
Kaplan-Meier method, and the curves were compared by
the log rank test. A p-value of <0.05 was defined as
statistically significant.
3. Results
3.1. Clinicopathological characteristics affecting
HCC recurrence
Overall, 17 of 126 patients (13.5%) had HCC recurrence
following LT. The median time for HCC recurrence was 11.3
months, with a range of 1.1e38.9 months. RFS rates were
92.3%, 85.2%, and 78.6% at 1, 3, and 5 years, respectively
(Fig. 1). For all the patients, the mean follow-up period
was 35.2 months. The clinicopathological features of the
patients with and without HCC recurrence after LT are lis-
ted and compared in Table 1. Meeting or not meeting theFigure 1 Cumulative Recurrence-Free Survival (RFS) curve of
HCC patients after LT. The 1-, 3-, and 5-year RFS rates were
92.3%, 85.2%, and 78.6%, respectively (n Z 126).Milan and UCSF transplantation criteria were significant
differences between the two groups.
Univariate analysis identified the following 11 factors:
age, AFP, preoperative locoregional therapy, tumor
number, maximum tumor size, sum of tumor sizes, histo-
logical grade, presence of satellite nodules, presence of
tumor capsules, presence of microvascular invasion, and
mean tumor necrosis with a p value of <0.1. Subsequently,
multivariate regression analysis of these 11 factors showed
that tumor number > three [p Z 0.024, hazard ratio
(HR) Z 3.249] and presence of microvascular invasion
(p Z 0.003, HR Z 4.336) were independent prognostic
factors of HCC recurrence (Table 2).
3.2. Patients with HCC recurrence after liver
transplantation
The clinical characteristics of 17 patients with HCC recur-
rence following LT are summarized in Table 3. There were
15 men and 2 women; their ages ranged from 32 to 63
years. Three patients received liver grafts from deceased
donors; the others, from living donors. Two patients with
Table 2 Univariate and multivariate analyses of clinicopathological factors affecting HCC recurrence of patients after liver
transplantation.
Factors Univariate analysis Multivariate analysis
p value HR 95% CI p value (HR, 95% CI)
Age (<55 versus 55 years) 0.093 0.397 0.152e1.035 NS
Sex (male versus female) 0.558 0.649 0.183e2.301 NS
Hepatitis B virus (positive versus negative) 0.525 1.492 0.492e4.526 NS
Hepatitis C virus (positive versus negative) 0.358 0.562 0.194e1.629 NS
Child Class (A, B, C) 0.556 d d NS
AFP (40 versus <40 ng/ml) 0.021 2.904 1.006e8.379 NS
MELD score (20 versus <20) 0.569 1.351 0.440e4.141 NS
Type of liver transplantation (DDLT versus LDLT) 0.157 2.378 0.870e6.500 NS
Preoperative locoregional therapy (>3 versus 3 months) 0.062 0.417 0.143e1.216 NS
GRWR (0.8% versus <0.8%) 0.817 1.188 0.298e4.741 NS
Tumor number (>3 versus 3) 0.005 7.680 1.839e32.082 0.024 (3.249, 1.166-9.050)
Maximum tumor size (>3 versus 3 cm) 0.077 2.328 0.754e7.193 NS
Sum of tumor size (>8 versus 8 cm) 0.059 2.807 0.570e13.812 NS
Histology grade (I/II versus III/IV) 0.026 0.284 0.093e0.865 NS
Presence of satellite nodule (yes versus no) 0.073 2.671 0.560e12.738 NS
Presence of tumor capsule (yes versus no) 0.098 0.416 0.147e1.179 NS
Presence of microvascular invasion (yes versus no) <0.001 4.767 1.293e17.600 0.003 (4.336, 1.649-11.403)
Mean tumor necrosis (60% versus <60%) 0.007 0.171 0.065e0.445 NS
HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; DDLT: deceased donor liver transplantation; LDLT: living donor liver trans-
plantation; MELD: model for end-stage liver disease; HR: hazard ratio; CI: confidence interval; GRWR; graft recipient weight ratio; NS: no
significance.
HCC recurrence after transplantation 131intrahepatic recurrence were successfully treated by TACE,
and no more recurrent HCCs were detected. Six patients
who had intrahepatic recurrence followed by extrahepatic
metastasis or synchronous intrahepatic and extrahepaticTable 3 Clinical features of patients with HCC recurrence afte
Patient
No.
Age/sex Tumor character Recurrent location an
Number Microvascular
invasion
1 48/M 4 () Brain, Lung
2 53/M 2 (þ) Liver (TACE), Lung (sy
3 63/M 7 () Liver (TACE)
4 38/M 1 (þ) Liver (TACE)
5 32/M 1 (þ) Liver (TACE), Lung (sy
6 54/M 9 () Intra-abdominal mass
liver and bone.
7 34/M 3 (þ) Liver (TACE), Bone
8 48/M 1 (þ) Liver (RFA), Lung (sys
9 55/M 1 () Bone and Lung (syste
10 51/M 7 () Abdominal wall (resec
11 41/M 7 (þ) Intra-abdominal mass
12 45/M 5 () Lung (resection)
13 53/M 3 () Liver (TACE), Lung (sy
14 48/M 1 () Bone (radiotherapy),
15 57/F 2 () Carcinomatosis
16 51/M 3 (þ) Lung (resection, twic
17 60/F 1 (þ) Liver (TACE), adrenal
LT: liver transplantation; TACE: transcatheter aterial chemoembo
RFA: radiofrequency ablation.recurrence were managed by locoregional therapy for
intrahepatic lesions along with systemic chemotherapy.
The remaining nine patients were found to have extrahe-
patic metastasis at the time when HCC recurrence wasr liver transplantation.
d management LT to HCC
recurrence
(months)
Follow-up after
HCC recurrence
(months)
Outcome
7.8 0.7 Dead
stemic C/T) 31.7 27.2 Alive
37.3 18.7 Alive
27.3 16.5 Alive
stemic C/T) 5.3 12.7 Dead
(resection), 39 12.2 Alive
1.2 21.1 Dead
temic C/T) 16.4 18.3 Dead
mic C/T) 5.4 3 Dead
tion) 7.0 49 Alive
(resection) 2.7 0.7 Dead
11.3 40 Alive
stemic C/T) 11.2 8.6 Dead
Lung (systemic C/T) 37.5 6.1 Dead
23.0 1.2 Alive
e) 14.3 13.3 Alive
gland, lung 10.9 3.7 Dead
lization; HCC: hepatocellular carcinoma; C/T: chemotherapy;
Figure 2 (A) Cumulative overall survival curves of patients according to the presence or absence of HCC recurrence, and patients
with HCC recurrence after LT had significantly poor survival (p < 0.001). (B) The cumulative survival curve of patients after HCC
recurrence. The median length of survival was 18.3 months. The 1- and 3-year survival rates were 63% and 35%, respectively
(n Z 17).
132 K.-M. Chan et al.detected, without intrahepatic HCC. Of these, four
patients (patient number 6, 10, 12, and 16) had undergone
surgical resection for isolated solitary extrahepatic metas-
tases, and two of them (patient number 10 and 12) were
alive and without any detectable recurrent tumor at the
end of this study. Unfortunately, one patient (patient
number 6) had systemic spreading including liver and bony
metastasis 6 months after resection of intra-abdominal
metastatic HCC. However, another patient (patient
number 16) had undergone two surgical resections for
solitary lung metastasis at intervals of 4.5 months, and no
more recurrence was detectable at the last follow-up. In
addition to surgical resection, there was no systemic
adjuvant therapy added in these four patients. A total of 15
out of 17 (88%) patients exhibited extrahepatic metastasis
during the follow-up examination.
However, the prognosis of patients with HCC recurrence
following LT remained very poor. The groups of patients
with and without HCC recurrence were compared and it
was found that HCC recurrence significantly affects the
outcome of patients undergoing LT (Fig. 2A, p < 0.001).
The analysis of survival curves showed that the overall
survival rates at 3 and 5 years were 52.9% and 45.4% in the
group of patients with HCC recurrence, while the corre-
sponding values were 87.5% and 87.5% in the group of
patients without HCC recurrence. After HCC recurrence,
the median length of patient survival was 18.3 months, andthe cumulative survival rates at 1 and 3 years were 63% and
35%, respectively (Fig. 2B).4. Discussion
LT offers the best chance to restore impaired liver function
and clear malignancy, and it has been considered an ideal
treatment modality for patients with severe liver cirrhosis
complicated by HCC.1,4,5,13 However, like patients who
have undergone surgical resection for malignancy, patients
with HCC who undergo LT live with a fear of tumor recur-
rence. For decades, cancer research has continued to
clarify prognostic factors and develop better treatment
strategies for cancer patients. Although prevention of HCC
recurrence through careful selection of patients is the best
strategy to improve the outcome of HCC patients under-
going LT, it is also very important to treat patients with HCC
recurrence following LT.
Many previous studies have reported several prognostic
factors capable of predicting the outcome of HCC patients
undergoing LT,7,14e17 and similar factors were also noted in
our study. Although univariate analysis identified 11 factors
for RFS, only tumor number and microvascular invasion were
shown to be independent prognostic factors. However, the
presence of microvascular invasion can only be accurately
assessed in the explanted liver, and pretransplantation
HCC recurrence after transplantation 133tumor biopsy is usually not suitable for all patients consid-
ering the patient’s clinical status and risk of tumor seeding.
Albeit low, it is estimated that approximately 2% of patients
experience tumor seeding following diagnostic biopsy,18,19
and liver biopsy is usually more complicated in patients
with severe liver cirrhosis. Additionally, multiple tumors
have significant histological heterogeneity, and it is not
practical to perform biopsy on each liver tumor even if liver
biopsy is proposed for each of the suspected lesions.20,21
However, numerous studies have reported that greater
tumor burden and elevation of AFP level is associated with
a greater chance of microvascular invasion,7,22e24 indicating
that tumor burden remains a key factor affecting the
outcome of HCC patients undergoing LT.
According to our data, an accurate diagnosis of the tumor
stage, in terms of number and size, at pretransplantation
evaluation is very crucial and a better way to predict patient
outcome. Nonetheless, patients with HCC are frequently
accompanied by liver cirrhosis as well as associated with
numerous regeneration nodules, making accurate diagnosis
of HCC even more challenging, and understaging can be an
issue encountered in patients previously treated with
locoregional therapy. Additionally, all imaging modalities
appear to be suboptimal for detecting small HCCs in
a cirrhotic liver.25 Therefore, pretransplantation determi-
nation of tumor number by an imaging study, at times, does
not correlate with the pathological tumor number of an
explanted liver, indicating that a radiologically determined
tumor number might be unable to reflect the real outcome in
patients. In our patient group, pathological staging had
shown that 21 out of 126 patients (16%) were transplanted
beyond UCSF criteria. The discrepancy of clinical and path-
ologic stage might be related to the fact that most patients
had received either pretransplantation bridging or down-
staging therapy. Therefore, dedicated multimodality
imaging examinations including MRI, dynamic liver CT scan,
and hepatic angiography are helpful to evaluate viable tumor
burden in such patients prior to LT.
As shown by our results and other reports,14,26 HCC
recurrence after LT seems to have a tendency to manifest
as extrahepatic metastasis or rampantly cause a systemic
spread after recurrence. With 88% of patients with recur-
rent HCC developing extrahepatic metastasis, the inci-
dence is much higher than that estimated with up to 42% of
patients experiencing extrahepatic metastatic HCC
following liver resection.27 This incidence may be related to
the patient’s immunosuppressed status after LT, in which
the patient’s immunity is unable to stop tumor progression.
Additionally, a study has also shown that overexposure to
immunosuppressants increases the risk of HCC recurrence
after LT,28 and recommended that tacrolimus should not
exceed 10 ng/mL of serum level. Although the limited
number of current study was unable to clarify the rela-
tionship of immunosuppressant and HCC recurrence, we
usually kept the serum level of tacrolimus between 5 ng/mL
and 10 ng/mL as much as possible. This level is not only for
preventing HCC recurrence but also considering that the
patient’s liver was relatively resistant to immunological
rejection as well as the low amount of immunosuppressants
required.
Similarly, early tumor recurrence occurred in patients
undergoing LT for HCC as seen in liver resection for patientswith HCC; there is currently no effective way to prevent
this situation. It might be argued that inadequate pre-
transplantation assessment was performed, but it is possible
that undetectable small tumor cells already systemically
traveled before LT. Additionally, the procedure of total
hepatectomy could also result in tumor dissemination during
the course of liver mobilization. Importantly, unexplored
factors other than pretransplantation evaluation and
surgical factors may play a principal role leading to early
HCC recurrence after LT, and further study in more patients
may be able to clarify this issue in the future.
Interestingly, the locations of recurrent HCC were
predominantly extrahepatic. A hypothetical explanation of
this phenomenon could be that the immunity offered by the
liver graft could work against the growth of host HCC within
the liver, directing the HCC to spread systemically. This
hypothesis, however, needs to be proven by a more
detailed scientific study. Once the recurrent HCC becomes
systemic, a poor prognosis is predictable, as shown by our
study. However, the aggressive approach with multimodal
treatment of the primary or recurrent HCC has greatly
improved the overall outcome of patients with HCC.29,30
The three patients who underwent surgical resection for
extrahepatic metastatic HCC were alive and remained
cancer-free until the end of this study, indicating that
aggressive management can provide a good outcome for
patients with HCC recurrence after LT.
In summary, we have identified two perioperative
prognostic factors of tumor recurrence in HCC patients
undergoing LT, and tumor number is the only factor that
can be assessed preoperatively. Thus, accurate evaluation
of tumor status before LT by radiological examination is
essential. Although the outcome of patients with HCC
recurrence after LT remains very poor because of
a tendency of HCC to recur as extrahepatic metastasis,
there is evidence proving that an aggressive procedure like
surgical resection of extrahepatic metastasis can be bene-
ficial in selected patients.References
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